Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 75-84

  Loboz, Katarzyna K ^a,b   Gross, Annette S ^a,b   Williams, Kenneth M ^a,b   Liauw, Winston S ^a,b   Day, Richard O ^a,b   Blievernicht, Julia K ^a,b   Zanger, Ulrich M ^a,b   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; DRUG METABOLITE; ERYTHROHYDROBUPROPION; HYDROXYBUPROPION; RIFAMPICIN; THREOHYDROBUPROPION; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ETHNOLOGY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NORMAL HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BUPROPION; DOPAMINE UPTAKE INHIBITORS; ENZYME INDUCTION; ENZYME INHIBITORS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HALF-LIFE; HUMANS; HYDROXYLATION; MALE; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; RIFAMPIN;

EID: 33745678731     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.010     Document Type: Article

References (36)

1. Lang T., Klein K., Fischer J., Nussler A.K., Neuhaus P., Hofmann U., et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11 (2001) 399-415
2. Hiratsuka M., Takekuma Y., Endo N., Narahara K., Hamdy S.I., Kishikawa Y., et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58 (2002) 417-421
3. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., et al. Hepatic CYP2B6 expression. gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307 (2003) 906-922
4. Lang T., Klein K., Richter T., Zibat A., Kerb R., Eichelbaum M., et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians. demonstration of phenotypic null alleles. J Pharmacol Exp Ther 331 (2004) 34-43
5. Zukunft J., Lang T., Richter T., Hirsch-Ernst K.I., Nussler A.K., Klein K., et al. A natural CYP2B6 TATA box polymorphism (-82T-> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67 (2005) 1772-1782
6. Klein K., Lang T., Saussele T., Barbosa-Sicard E., Schunck W.-H., Eichelbaum M., et al. Genetic variability of CYP2B6 in populations of African and Asian origin. allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15 (2005) 861-873
7. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., et al. CYP2B6 mediates the in vitro hydroxylation of bupropion. potential drug interactions with other antidepressants. Drug Metab Dispos 28 (2000) 1176-1183
8. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism. implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306 (2003) 287-300
9. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53 (1993) 5629-5637
10. Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29 (2001) 1480-1484
11. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., and Waxman D.J. Human cytochrome P4502B6. interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25 (1997) 985-993
12. Stresser D.M., and Kupfer D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27 (1999) 517-525
13. Hoffman S.M., Nelson D.R., and Keeney D.S. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11 (2001) 687-698
14. Faucette S.R., Hawke R.L., Lecluyse E.L., Shord S.S., Yan B., Laethem R.M., et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28 (2000) 1222-1230
15. Faucette S.R., Hawke R.L., Shord S.S., Lecluyse E.L., and Lindley C.M. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29 (2001) 1123-1129
16. Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U.M., Murdter T.E., et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13 (2003) 619-626
17. Palovaara S., Pelkonen O., Uusitalo J., Lundgren S., and Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74 (2003) 326-333
18. Turpeinen M., Tolonen A., Uusitalo J., Jalonen J., Pelkonen O., and Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77 (2005) 553-559
19. Jefferson J.W., Pradko J.F., and Muir K.T. Bupropion for major depressive disorder. pharmacokinetic and formulation considerations. Clin Ther 27 (2005) 1685-1695
20. Edwards R.J., Price R.J., Watts P.S., Renwick A.B., Tredger J.M., Boobis A.R., et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31 (2003) 282-288
21. Goodwin B., Moore L.B., Stoltz C.M., McKee D.D., and Kliewer S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60 (2001) 427-431
22. Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton L.A., Krueger L.A., et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31 (2003) 421-431
23. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes. studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299 (2001) 849-857
24. Faucette S.R., Wang H., Hamilton G.A., Jolley S.L., Gilbert D., Lindley C., et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32 (2004) 348-358
25. Lopez-Cortes L.F., Ruiz-Valderas R., Viciana P., Alarcon-Gonzalez A., Gomez-Mateos J., Leon-Jimenez E., et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41 (2002) 681-690
26. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
27. Loboz K.K., Gross A.G., Ray J., and McLachlan A.J. HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 823 (2005) 115-121
28. Ingelman-Sundberg M, Daly AK, Nebert DW, editors. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: URL:http://www.imm.ki.se/cypalleles. Accessed September 2005.
29. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., and Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37 (1997) 737-743
30. Haustein K.O. Bupropion. pharmacological and clinical profile in smoking cessation. Int J Clin Pharmacol Ther 41 (2003) 56-66
31. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., and Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15 (2001) 71-75
32. Fleming R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17 (1997) S146-S154
33. Van Schaik R.H. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit 26 (2004) 236-240
34. Johnston J.A., Ascher J., Leadbetter R., Schmith V.D., Patel D.K., Durcan M., et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 62 (2002) S11-S24
35. Johnston J.A., Fiedler-Kelly J., Glover E.D., Sachs D.P.L., Grasela T.H., and De Veaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 3 (2001) 131-140
36. Deurenberg P., Deurenberg-Yap M., and Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 3 (2002) 141-146